top of page
Search

Can Weight-Loss Jabs Help With PCOS? What the New UK Research Says

Clinical Base
2 days ago
4 min read
A calm, modern GP consulting room desk with a stethoscope and a tablet, representing women's metabolic health care

If you have polycystic ovary syndrome, or PCOS, you've probably heard a lot of confusing advice about weight and hormones. Now there's some big UK news to add to the mix: the condition is getting its first-ever national NHS treatment guideline, a new name, and a fresh research project looking at whether weight-loss jabs like Mounjaro and Ozempic could help. Here's what's actually going on, explained simply.


What is PCOS?

PCOS stands for polycystic ovary syndrome. According to the NHS, it's a common condition affecting how a woman's ovaries work. It can cause irregular periods, acne, extra hair growth, and ovaries with lots of small fluid-filled sacs called follicles. PCOS is also closely linked to insulin resistance, when the body doesn't respond properly to the hormone insulin. This makes weight harder to manage and raises the risk of type 2 diabetes later in life.


PCOS affects somewhere between one in ten and one in eight women of reproductive age in the UK, and it's the single biggest cause of female infertility, because it can stop ovulation (the release of an egg) happening regularly.


A new name: PMOS

In July 2026, the National Institute for Health and Care Excellence (NICE), which sets NHS treatment guidelines, published its first-ever draft national guideline for PCOS. As part of this, the condition is being renamed "polyendocrine metabolic ovarian syndrome," or PMOS for short.


Sharon Manship, a patient representative who helped write the guideline and who herself took more than ten years to get diagnosed, said her hope is that the new guideline means people "will be taken seriously, diagnosed earlier and provided with evidence-based support and care from healthcare professionals from the outset." The new name is meant to better reflect that this isn't just about the ovaries. It's a whole-body, hormone-and-metabolism condition.


The draft guideline recommends an annual health check-up for anyone diagnosed, because PMOS is linked to higher risks of type 2 diabetes, heart problems, sleep apnoea, liver disease, and mental health difficulties. It also sets out existing medicines doctors can use off-label, such as progestogens for irregular periods, combined contraceptive pills or spironolactone for excess hair growth, and metformin for metabolic issues. Final guidance is expected in December 2026.


Importantly, the draft guideline says weight-loss medications should not currently be used specifically to treat fertility problems in people with PMOS, except as part of proper research studies. This matters, because it's exactly the question the next bit of news is trying to answer.


A new UK study on weight-loss jabs and PCOS

Also in 2026, researchers at Aston University and Sandwell and West Birmingham NHS Trust were awarded a £60,000 NHS research grant to study whether GLP-1 medicines, specifically Mounjaro (tirzepatide) and Ozempic (semaglutide), could help women with PCOS.


These medicines work by copying a gut hormone called GLP-1, which helps the body feel fuller for longer and process sugar more steadily. They're already used for weight management and type 2 diabetes. The idea the researchers are testing is that if these medicines help with weight and insulin resistance, they might also help restore more regular ovulation and improve fertility for some women with PCOS, alongside general health benefits.


The project, led by Dr Shagaf Bakour and Dr Hoda Harb, has two stages. First, the team will review all the existing research evidence to see what's already known and where the gaps are. Then, if they get the right approvals, they'll run a real-world study linking fertility clinics, GP records, and weight-management services to see how these medicines actually work in practice for women with PCOS.


"The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care." — Dr Shagaf Bakour, Aston University

What this means for you right now

It's exciting that serious research is finally catching up with a condition that's affected millions of women for a long time. But here's where things stand today, in October 2026: GLP-1 medicines are not currently licensed or recommended specifically for treating PCOS or PCOS-related fertility problems. The research above is still at an early stage, and the new NICE draft guideline is clear that these medicines shouldn't be used for PCOS fertility treatment outside of research settings.


If you have PCOS and are also living with excess weight, existing NHS and NICE weight-management pathways may still be an option, assessed as usual by a GP or specialist. Day-to-day management of PCOS still comes down to the basics with solid evidence behind them: regular movement, a balanced diet, and, where appropriate, the medicines named in the new draft guideline, such as metformin.


If you're thinking about your weight, fertility, or any medication, the right first step is always a conversation with your GP or a specialist. Any weight-loss medicine needs a proper medical assessment and a prescription from a qualified clinician, and nobody should expect one to fix fertility problems on its own, at least not yet.


The takeaway

PCOS is finally getting more attention, a clearer name, proper NHS guidance, and dedicated UK research into new treatment options. But weight-loss jabs are not yet an approved PCOS fertility treatment. For now, they remain under study, and anyone considering any weight-loss medicine should talk to a qualified clinician first.


References

 
 
 

Comments

bottom of page